675
Participants
Start Date
October 21, 2024
Primary Completion Date
January 31, 2029
Study Completion Date
August 31, 2030
GS-1720
Tablets administered orally without regard to food
GS-4182
Tablets administered orally without regard to food
Bictegravir/emtricitabine/tenofovir alafenamide
Tablets administered orally without regard to food
GS-1720/GS-4182 FDC
Tablets administered orally without regard to food
Placebo to Match BVY
Tablets administered orally without regard to food
Placebo to Match GS1720/GS-4182 FDC
Tablets administered orally without regard to food
CRISMO Research Center, Germiston
The Aurum Institute Tembisa Clinic 4, Tembisa
WITS RHI Research Centre, Johannesburg
Durban International Clinical Research Site, Enhancing Care Foundation, Durban
Unidade Local de Saúde de Santo António, E.P.E., Porto
Clinical Research Institute of South Africa (CRISA), KwaZulu-Natal
Synergy Biomed Research Institute, East London
FPD Ndevana Community Research Site, Ndevana
Hospital Clinic de Barcelona, Barcelona
JOSHA Research, Bloemfontein
NYU Langone Health Vaccine Center, New York
Georgetown University Medical School, Washington D.C.
ICH Study Center GmbH & Co. KG, Hamburg
Hospital Clinico San Carlos, Madrid
Hospital Universitario Virgen de la Victoria, Málaga
Medical University of South Carolina (MUSC) Research Nexus, Charleston
Emory University Hospital Midtown Infectious Disease Clinic, Atlanta
Medizinische Hochschule Hannover, Klinik für Rheumatologie und Immunologie, Gebäude K14, Hanover
Mercer University, Department of Internal Medicine, Macon
Midland Florida Clinical Research Center, LLC, DeLand
Orlando Immunology Center, Orlando
Floridian Clinical Research, LLC, Miami Lakes
Triple O Research Institute, P.A., West Palm Beach
Midway Immunology and Research Center, Ft. Pierce
UAB 1917 Research Clinic, Birmingham
Hospital Universitario Alvaro Cunqueiro, Pontevedra
University of Mississippi Medical Center, Jackson
Universitätsmedizin Essen, Universitätsklinikum Essen, Klinik für Dermatologie, Venerologie und Allergologie, HPSTD-Ambulanz, Essen
Hospital Arnau de Vilanova de Valencia, Valencia
Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik I, Immunologische Studienambulanz, Bonn
Prism Health North Texas, Aids Arms, Dallas
North Texas Infectious Diseases Consultants, PA, Dallas
Texas Centers for Infectious Disease Associates, Fort Worth
St Hope Foundation, Inc., Bellaire
UT Health San Antonio, San Antonio
Klinikum rechts der Isar, Technische Universität München, Klinik und Poliklinik für Innere Medizin II, München
Mills Clinical Research, West Hollywood
The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance
MultiCare Rockwood Main Clinic, Spokane
Spitalul Clinic De Boli Infectioase Cluj-Napoca, Cluj-Napoca
Saint Michael's Medical Center, Newark
Clinique Médicale L'Actuel, Montreal
Chronic Viral Illness Service / McGill University Health Centre, Montreal
Ottawa Hospital Research Institute, Ottawa
Wojewódzki Szpital Obserwacyjno-Zakaźny im. Tadeusza Browicza, Bydoszcz
Punkt Zdrowia, Gdansk
Samodzielny Publiczny Wojewódzki Szpital Zespolony w Szczecinie, Szczecin
Unidade Local de Saude de Amadora Sinatra EPE, Hospital Prof. Doutor Fernando Fonseca, Amadora
Unidade Local de Saúde de Lisboa Ocidental E.P.E. - Hospital Egas Moniz, Lisbon
Unidade Local de Saúde de Santo Maria E.P.E. - Hospital Santa Maria, Lisbon
Unidade Local de Saúde de São João E.P.E., Porto
HOPE Clinical Research, San Juan
Proyecto ACTU, San Juan
Institutul National De Boli Infectioase Prof. Dr. Matei Bals, Bucharest
Spitalul Clinic De Urgenta Prof Dr Agrippa Ionescu, Bucharest
Clinical Hospital of Infectious Diseases and Pneumophysiology Dr. Victor Babes Timisoara, Timișoara
Spitalul Clinic de Boli Infectioase Constanta, Constanța
Lead Sponsor
Gilead Sciences
INDUSTRY